AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
What Is Chronic Lung Disease? A chronic lung disease is a type of disease that prevents the lungs and respiratory system from working correctly. The main job of the respiratory system is to take in ...
Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...
Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...
AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results